Moody Aldrich Partners’s Aerie Pharmaceuticals AERI Stock Holding History

Moody Aldrich Partners’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-36,980	Closed	-$1.76M	–	132
2019 Q1	$1.76M	Buy	+36,980	New	+$1.63M	0.49%	80
2018 Q4	–	Sell	-76,537	Closed	-$4.71M	–	116
2018 Q3	$4.71M	Buy	76,537 +11,882	+18%	+$764K	1.36%	29
2018 Q2	$4.37M	Buy	64,655 +23,498	+57%	+$1.31M	1.55%	17
2018 Q1	$2.23M	Buy	41,157 +9,201	+29%	+$515K	1.43%	26
2017 Q4	$1.91M	Buy	31,956 +10,430	+48%	+$632K	1.55%	19
2017 Q3	$1.05M	Buy	+21,526	New	+$1.17M	1.08%	46

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Moody Aldrich Partners's AERI Position: Q2 2019 in Review

Moody Aldrich Partners sold out of Aerie Pharmaceuticals (AERI) in Q2 2019, closing a stake of 36,980 shares — an estimated $1.76M sold.

Moody Aldrich Partners first reported a position in AERI in Q3 2017 and held it in 6 quarters. The position peaked at $4.71M in Q3 2018. 167 funds tracked by Wall St. Rank hold AERI as of Q2 2019.

Moody Aldrich Partners reported no remaining Aerie Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Moody Aldrich Partners sold 36,980 Aerie Pharmaceuticals shares in Q2 2019, an estimated $1.76M.
Moody Aldrich Partners first reported a position in Aerie Pharmaceuticals in Q3 2017 and held it in 6 quarters.
Moody Aldrich Partners's Aerie Pharmaceuticals position peaked at $4.71M in Q3 2018.
167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2019.

Based on Moody Aldrich Partners's 13F filing for Q2 2019, filed 26 Jul 2019.